Early instauration granulomatous pneumonitis associated with use of etanercept in seronegative spondyloarthropathy: Case report

Abstract

Spondyloarthropathies are a group of chronic inflammatory disorders that involve the joints of the axial skeleton, peripheral joints and have extra-articular manifestations. Treatment includes inhibitors of tumor necrosis factor α. Currently there are five approved inhibitors: a soluble receptor, Etanercept and four monoclonal.Etanercept has very low toxicity with pulmonary adverse reactions being very rare. We present the case of a patient who developed respiratory symptoms and pulmonary infiltrates of rapid evolution after the third dose of treatment with Etanercept.

Keywords

• Etanercept
• Pulmonary granulomatosis
• TNF-α
• Anti-TNF
• Spondyloarthropathy
• Case report